9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We have used homozygous albumin enhancer/promoter-driven urokinase-type plasminogen activator/severe combined immunodeficient (uPA/SCID) mice as hosts for chimeric mice with humanized livers. However, uPA/SCID mice show four disadvantages: the human hepatocytes (h-heps) replacement index in mouse liver is decreased due to deletion of uPA transgene by homologous recombination, kidney disorders are likely to develop, body size is small, and hemizygotes cannot be used as hosts as more frequent homologous recombination than homozygotes. To solve these disadvantages, we have established a novel host strain that has a transgene containing albumin promoter/enhancer and urokinase-type plasminogen activator cDNA and has a SCID background (cDNA-uPA/SCID). We applied the embryonic stem cell technique to simultaneously generate a number of transgenic lines, and found the line with the most appropriate levels of uPA expression—not detrimental but with a sufficiently damaged liver. We transplanted h-heps into homozygous and hemizygous cDNA-uPA/SCID mice via the spleen, and monitored their human albumin (h-alb) levels and body weight. Blood h-alb levels and body weight gradually increased in the hemizygous cDNA-uPA/SCID mice and were maintained until they were approximately 30 weeks old. By contrast, blood h-alb levels and body weight in uPA/SCID chimeric mice decreased from 16 weeks of age onwards. A similar decrease in body weight was observed in the homozygous cDNA-uPA/SCID genotype, but h-alb levels were maintained until they were approximately 30 weeks old. Microarray analyses revealed identical h-heps gene expression profiles in homozygous and hemizygous cDNA-uPA/SCID mice were identical to that observed in the uPA/SCID mice. Furthermore, like uPA/SCID chimeric mice, homozygous and hemizygous cDNA-uPA/SCID chimeric mice were successfully infected with hepatitis B virus and C virus. These results indicate that hemizygous cDNA-uPA/SCID mice may be novel and useful hosts for producing chimeric mice for use in future long-term studies, including hepatitis virus infection analysis or drug toxicity studies.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          Hepatitis C virus replication in mice with chimeric human livers.

          Lack of a small animal model of the human hepatitis C virus (HCV) has impeded development of antiviral therapies against this epidemic infection. By transplanting normal human hepatocytes into SCID mice carrying a plasminogen activator transgene (Alb-uPA), we generated mice with chimeric human livers. Homozygosity of Alb-uPA was associated with significantly higher levels of human hepatocyte engraftment, and these mice developed prolonged HCV infections with high viral titers after inoculation with infected human serum. Initial increases in total viral load were up to 1950-fold, with replication confirmed by detection of negative-strand viral RNA in transplanted livers. HCV viral proteins were localized to human hepatocyte nodules, and infection was serially passaged through three generations of mice confirming both synthesis and release of infectious viral particles. These chimeric mice represent the first murine model suitable for studying the human hepatitis C virus in vivo.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Near completely humanized liver in mice shows human-type metabolic responses to drugs.

            Human hepatocytes were transplanted into urokinase-type plasminogen activator-transgenic SCID mice (uPA/SCID mice), which are immunodeficient and undergo liver failure. The transplanted cells were characterized in terms of their in vivo growth potential and functions. The human hepatocytes progressively repopulated the murine host liver. However, the recipients died when the replacement index (RI) of the human hepatocytes exceeded 50%. The hosts (chimeric mice) survived at RI >50% when treated with a drug that has anti-human complement factor activity, and these mice developed livers with RI values as high as 96%. In total, 36 chimeric mice were generated, and the rate of successful engraftment was as high as 92%. The yield of chimeric mice with RI >70% was 32%. The human hepatocytes in the murine host liver expressed mRNAs for a variety of human cytochrome P450 (hCYP) subtypes, in a manner that was similar to the donor liver. The mRNAs for hCYP3A4 and hCYP1A1/2 were induced in the liver in a CYP type-specific manner when the mice were treated with rifampicin and 3-methylcholanthrene, respectively. These results indicate that human hepatocytes that propagate in mice retain their normal pharmacological responses. We conclude that the chimeric mouse developed in the present study is a useful model for assessing the functions and pharmacological responses of human hepatocytes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The reconstituted 'humanized liver' in TK-NOG mice is mature and functional.

              To overcome the limitations of existing models, we developed a novel experimental in vivo platform for replacing mouse liver with functioning human liver tissue. To do this, a herpes simplex virus type 1 thymidine kinase (HSVtk) transgene was expressed within the liver of highly immunodeficient NOG mice (TK-NOG). Mouse liver cells expressing this transgene were ablated after a brief exposure to a non-toxic dose of ganciclovir (GCV), and transplanted human liver cells are stably maintained within the liver (humanized TK-NOG) without exogenous drug. The reconstituted liver was shown to be a mature and functioning "human organ" that had zonal position-specific enzyme expression and a global gene expression pattern representative of mature human liver; and could generate a human-specific profile of drug metabolism. The 'humanized liver' could be stably maintained in these mice with a high level of synthetic function for a prolonged period (8 months). This novel in vivo system provides an optimized platform for studying human liver physiology, including drug metabolism, toxicology, or liver regeneration. Copyright © 2011 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, CA USA )
                1932-6203
                4 November 2015
                2015
                : 10
                : 11
                : e0142145
                Affiliations
                [1 ]PhoenixBio Co., Ltd., Higashihiroshima, Hiroshima, Japan
                [2 ]Liver Research Project Center, Hiroshima University, Hiroshima, Japan
                [3 ]Chugai Research Institute for Medical Science, Inc., Gotemba, Shizuoka, Japan
                [4 ]Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
                [5 ]Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan
                [6 ]Sekisui Medical Co., Ltd., Tokyo, Japan
                Centro de Investigación en Medicina Aplicada (CIMA), SPAIN
                Author notes

                Competing Interests: CT, SH, HO, HY, H. Sanada, M. Kakuni, AS, Y. Kojima, and YI are employed by PhoenixBio, Co., Ltd. Y. Kawase, NAW and HT are employed by Chugai Research Institute for Medical Science, Inc. MS and KJ are employed by Chugai Pharmaceutical Co., Ltd. SN is employed by Sekisui Medical Co., Ltd. Furthermore, CT, Y. Kawase, SH, HO, KJ, and M. Kohara are the authors of the patent (PCT/JP2013/062806) utilized in this study regarding the cDNA-uPA/SCID chimeric mouse produced at PhoenixBio Co., Ltd., Tokyo Metropolitan Institute of Medical Science, and Chugai Pharmaceutical Co., Ltd. These affiliations do not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

                Conceived and designed the experiments: CT MS KJ M. Kohara. Performed the experiments: Y. Kawase Y. Kojima YT SH HO HY H. Sanada AS YI H. Shitara NAW HT SN. Analyzed the data: CT MK SN KJ M. Kohara. Wrote the paper: CT M. Kakuni SN KJ M. Kohara.

                [¤a]

                Current address: Institute of Immunology Co. Ltd., Tokyo, Japan

                [¤b]

                Current address: Chugai Pharmaceutical Co. Ltd., Gotemba, Shizuoka, Japan

                Article
                PONE-D-15-19814
                10.1371/journal.pone.0142145
                4633119
                26536627
                d8ea58b4-f3d2-458e-90ad-c7f4c6af11d7
                Copyright @ 2015

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

                History
                : 8 May 2015
                : 19 October 2015
                Page count
                Figures: 9, Tables: 4, Pages: 20
                Funding
                This study was funded by PhoenixBio, Co., Ltd., Chugai Research Institute for Medical Science, Chugai Pharmaceutical Co., Ltd., and Sekisui Medical Co., Ltd., which provided support in the form of salaries for authors [CT, Y. Kawase, SH, HO, HY, H. Sanada, M. Kakuni, AS, Y. Kojima, YI, NAW, HT, MS, SN, KJ], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Custom metadata
                Data are available from the Gene Expression Ominibus. The Accession No. is GSE69936.

                Uncategorized
                Uncategorized

                Comments

                Comment on this article